Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5733542 A
Publication typeGrant
Application numberUS 08/377,771
Publication date31 Mar 1998
Filing date24 Jan 1995
Priority date16 Nov 1990
Fee statusPaid
Also published asWO1996023058A1
Publication number08377771, 377771, US 5733542 A, US 5733542A, US-A-5733542, US5733542 A, US5733542A
InventorsStephen E. Haynesworth, Arnold I. Caplan, Stanton L. Gerson, Hillard M. Lazarus
Original AssigneeHaynesworth; Stephen E., Caplan; Arnold I., Gerson; Stanton L., Lazarus; Hillard M.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Enhancing bone marrow engraftment using MSCS
US 5733542 A
Abstract
Method and preparations for enhancing bone marrow engraftment in an individual by administering (i) a culturally expanded mesenchymal stem cell preparation and (ii) a bone marrow graft. The mesenchymal stem cells are administered in an mount effective to promote engraftment of the bone marrow.
Images(5)
Previous page
Next page
Claims(8)
What is claimed is:
1. A method for enhancing bone marrow engraftment in an individual in need thereof which comprises administering to said individual (i) isolated, homogeneous mesenchymal stem cells and (ii) a bone marrow graft, wherein said mesenchymal stem cells are administered in an amount effective to promote engraftment of said bone marrow in said individual.
2. The method of claim 1 wherein the mesenchymal stem cells are administered by intravenous injection or by injection directly to the site of intended activity.
3. The method of claim 1 wherein at least one of (i) the mesenchymal stem cells and (ii) the bone marrow graft is administered intravenously.
4. The method of claim 1 wherein at least one of (i) the mesenchymal stem cells and (ii) the bone marrow graft is injected into said cavity.
5. The method of claim 1 wherein the mesenchymal stem cells are autologous.
6. The method of claim 1 wherein the mesenchymal stem cell preparation is administered concurrently with the bone marrow graft.
7. The method of claim 6 wherein the mesenchymal stem cells are introduced into said individual in a cell suspension also containing bone marrow graft cells.
8. The method of claim 1 wherein the mesenchymal stem cell preparation is administered to the individual prior to administration of the bone marrow graft.
Description

This is a continuation-in-part of U.S. Ser. No. 08/193,262, filed Feb. 8, 1994 (U.S. Pat. No. 5,486,359 issued on Jan. 23, 1996), which is a continuation-in-part of U.S. Ser. No. 08/034,272, filed Mar. 22, 1993 (abandoned), which is a continuation-in-part of U.S. Ser. No. 07/716,917 filed Jun. 18, 1991 (abandoned), which is a continuation-in-part of U.S. Ser. No. 07/615,430 filed Nov. 16, 1990 (abandoned); and a continuation-in-part of U.S. Ser. No. 08/038,517, filed Mar. 29, 1993 (abandoned), which is a divisional of U.S. Ser. No. 07/614,912, filed Nov. 16, 1990 (U.S. Pat. No. 5,226,914 issued on Jul. 13, 1993); and a continuation-in-part of U.S. Ser. No. 08/038,512, filed Mar. 29, 1993 (abandoned), which is a divisional of 07/614,915, filed Nov. 16, 1990 (U.S. Pat. No. 5,197,985 issued on Mar. 30, 1993).

The present invention is directed to various methods and devices for using mesenchymal stem cells (MSCs) to enhance bone marrow engraftment. Mesenchymal stem cells are the formative pluripotent blast cells found in the bone that are capable of differentiating into any of the specific types of connective tissues (i.e., the tissues of the adipose, areolar, osseous, cartilaginous, elastic, and fibrous connective tissues) depending upon various environmental influences. Although these cells are normally present at very low frequencies in bone marrow and other mesenchymal tissues, the inventors of the present invention have discovered a process for isolating, purifying, and greatly replicating the mesenchymal stem cells in culture, i.e. in vitro. This discovery is the subject of co-pending U.S. patent application Ser. No. 193,262, filed Feb. 8, 1994. The methods and devices of the invention utilize such isolated and culture-expanded mesenchymal stem cells (MSCs). Under selected conditions, they can be induced to differentiate into different types of skeletal and connective tissues such as bone, cartilage, tendon, ligament, muscle, other connective tissues and marrow stroma.

The marrow stroma provides the scaffolding as well as soluble factors which direct and support blood cell synthesis, i.e., hematopoiesis. The present invention is directed to a method to improve the process of bone marrow transplantation which is used to regenerate blood cells and marrow tissue in patients where their marrow is depleted or destroyed, such as, for example, during intensive radiation and chemotherapy treatment. Along this line, the inventors have discovered that, after lethal doses of radiation, culture-expanded MSCs can increase survival and decrease the time of blood and marrow cell regeneration when transplanted with complete bone marrow.

The present invention provides a method for enhancing the regeneration of marrow tissue through improved bone marrow transplantation using MSCs. The method for enhancing bone marrow engraftment comprises administering to an individual in need thereof, (i) mesenchymal stem cells and (ii) a bone marrow graft, wherein said mesenchymal stem cells are administered in an amount effective to promote engraftment of the bone marrow in the individual. More particularly, one embodiment of the invention is directed to a method for using a culture medium comprised of Dulbecco's Modified Essential Medium with low glucose (DMEM-LG) or medium 199 plus 1% human albumin as a vehicle or carrier for MSCs which, when administered systemically, will migrate, or home, to the marrow cavity and differentiate into marrow stroma, thereby regenerating the marrow stroma. The MSCs can be administered systemically, e.g., intravenously, into various delivery sites or directly into the bone.

A further aspect of the present invention is directed to the timing of injection of the MSCs into the patient relative to the bone marrow transplantation. In one embodiment, the MSCs are injected simultaneously with the bone marrow. In another embodiment, the MSCs are administered before or after the injection of bone marrow.

The present invention is useful to enhance the effectiveness of bone marrow transplantation as a treatment for cancer. The treatment of cancer by x-irradiation or alkylating therapy destroys the bone marrow microenvironment as well as the hematopoietic stem cells. The current treatment is to transplant the patient after marrow ablation with bone marrow which has been previously harvested and cryopreserved. However, because the bone marrow microenvironment is destroyed, bone marrow engraftment is delayed until the stromal environment is restored. As a result, a critical aspect of the present invention is directed to the advantages of transplanting isolated, purified, culture-expanded MSCs to accelerate the process of stromal reconstitution and ultimately marrow engraftment.

Modes of administration of the MSC preparation include but are not limited to systemic intravenous injection and injection directly to the intended site of activity. The preparation can be administered by any convenient route, for example by infusion or bolus injection and can be administered together with other biologically active agents. Administration is preferably systemic.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of the MSCs, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to medium 199 plus 1% serum albumin, saline, buffered saline, dextrose, water, and combinations thereof. The formulation should suit the mode of administration.

In a preferred embodiment, the MSC preparation or composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a local anesthetic to ameliorate any pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a cryopreserved concentrate in a hermetically sealed container such as an ampoule indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The method of the invention can be altered, particularly by (1) increasing or decreasing the time interval between injecting MSCs and implanting the tissue; (2) increasing or decreasing the amount of MSCs injected; (3) varying the number of MSC injections; (4) varying the method of delivery of MSC; or (5) varying the source of MSCs. Although MSCs derived from the tissue donor is preferable, the MSCs can be obtained from other individuals or species, or from genetically-engineered inbred donor strains, or from in vitro cell culture.

The MSC preparation is used in an amount effective to promote engraftment of bone marrow in the recipient. In general, such amount is at least 1×104 MSC per kg of body weight and most generally need not be more than 7×105 MSC/kg. Preferably, it is at least about 2×105 MSC/kg prior to graft introduction and usually need not be more than about 7×105 MSC/kg. The MSC preparation may be administered concurrently with the bone marrow transplant or for a period prior to graft introduction of at least about 7 days but generally not to exceed 30 days, with a typical therapeutic treatment period of 7 to 14 days. The MSC preparation preferably is administered either intravenously one to three times per day, and may be adjusted to meet optimal efficacy and pharmacological dosing.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical preparation of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

EXAMPLE 1 Isolation, Purification and Cultural Expansion of Marrow-Derived Mesenchymal Stem Cells

Marrow in femoral head cancellous bone pieces was obtained from patients with degenerative joint disease during hip or knee joint replacement surgery. In addition, marrow was also obtained by iliac aspirate from normal donors and oncology patients who were having marrow harvested for future bone marrow transplantation. All of the oncology patients had malignancies unrelated to the stromal cells and the stromal cells expressed normal karyotype.

Marrow for cell culture was prepared from plugs of cancellous bone marrow as follows. Plugs of cancellous bone marrow (0.5-1.5 ml) were transferred to sterile tubes to which 25 ml Dulbecco's Modified Eagles Medium with low glucose (DMEM-LG) (GIBCO, Grand Island, N.Y.) with selected batches of 10% fetal bovine serum (complete medium) was added. The tubes were vortexed to disperse the marrow, then spun at 1000 rpm for 5 minutes to pellet cells and bone pieces. The supernatant and fat layer were removed and the marrow and bone were reconstituted in 5 ml complete medium and vortexed to suspend the marrow cells. The suspended cells were collected with a 10 ml syringe fitted with a 16 gauge needle and transferred to separate tubes. Bone pieces were reconstituted in 5 ml of complete medium and the marrow cells were collected as before. Collection of marrow cells was considered complete when a pellet of yellowish-white cancellous bone pieces was all that remained in the original tube. Marrow cells were separated into a single cell suspension by passing them through syringes fitted with 18 and 20 gauge needles. Cells were spun at 1000×g for 5 minutes after which the fat layer and supernatant were removed. Cells were reconstituted in complete medium, counted with a hemocytometer (red blood cells were lysed prior to counting with 4% acetic acid), and plated in 100 mm dishes at 50×106 nucleated cells/dish.

Marrow for cell culture was prepared from aspirated bone marrow as follows. Aspirate marrow (5-10 ml) was transferred to sterile 50 ml plastic centrifuge tubes to which 20 ml complete medium was added. The tubes were spun at 1,500 rpm for 5 minutes to pellet the cells. The supernatant and fat layer were removed and the cell pellets were resuspended to 5 ml with complete medium. The cell suspensions then were loaded onto 70% Percoll (Sigma, St. Louis, Mo.) gradients with a 10 ml pipette and spun at 2,000 rpm (460×g) in a GS34 rotor for 15 minutes. In order to harvest the cells, the tube is marked just below the high concentrated band of platelets, about 25% to 35% of the way down the tube. (Pooled density=1.03g/ml.) Using a 10 ml pipette, the medium is aspirated off from the top down to the marked line (approximately 12-14 ml). the collected fraction is transferred to a 50 ml conical plastic tube. 30 ml of complete medium then is added to the tube and centrifuged for 5 minutes at 1,500 rpm. The supernatant then is removed and discarded.

The cells then are resuspended in 7 ml of complete medium, and a uniform cell suspension is generated by piperting cells up and down with a 10 ml pipette. The cells are counted by taking 20 μl of uniform cell suspension, and adding 20 μl of 4% acetic acid to the cell suspension. The suspension is mixed and transferred to a hemocytometer, and the cells are counted.

Cell concentration then is adjusted with complete medium to 50×106 cells per 7 ml. 7 ml of cells (50×106 cells) then are plated per 100 mm culture plate.

The marrow mesenchymal stem cells were purified and expanded as follows. Marrow cells from either the femoral head cancellous bone or the iliac aspirate were cultured in complete medium (i.e., DMEM-LG medium with 10% fetal bovine serum) at 37° C. in humidified atmosphere containing 95% air and 5% CO2. On day 3 after plating, nonadherent cells were removed from the cultures by aspirating the original medium from the plates and replacing the original medium with 7 ml of fresh complete medium. Subsequent medium changes were performed every 3 to 4 days. This process of removing the non-adherent cells during culture media changes results in purification of the mesenchymal stem cells which selectively adhere to the culture plates. When primary culture dishes became nearly confluent, the medium was removed and each plate rinsed with 7 ml of sterile Tyrode's solution. The cells were detached with 4 ml of 0.25% trypsin with 0.1 mM EDTA (GIBCO) for 5 minutes at 37° C. The action of trypsin was stopped with 2 ml of calf serum. The cells then were collected with a 10 ml pipette and centrifuged for 5 minutes at 1,500 rpm. The supernatant then is removed, and the cells resuspended from each plate in 21 ml complete medium, and a uniform cell suspension is generated by gently pipetting the cells up and down in the pipette. The cells from each culture then are counted and plated in three new 100 ml plates in 7 ml complete medium. The three new plates of cells are termed first passage cultures. First passage cells then were allowed to expand until they became near confluent, and were then replated as described above to create second passage cultures. At each passage, aliquots of cells were cryopreserved in 90% fetal bovine serum with 10% DMSO (freezing medium).

EXAMPLE 2

Mesenchymal stem cells were obtained from 10 ml of autologous human bone marrow collected either at the time of autologous bone marrow harvest, or during a routine diagnostic bone marrow examination, from the iliac crest. These mesenchymal stem cells were culture expanded and infused into 14 patients who had hematologic malignancies, but had no evidence of active malignancy, and had not received chemotherapy or radiation therapy for at least 4 weeks before collection of mesenchymal stem cells. Five patients each received 1 million autologous mesenchymal stem cells, five patients each were given 10 million mesenchymal stem cells, and four patients each received 50 million mesenchymal stem cells. Toxicity for each patient was determined according to the National Cancer Institute toxicity grading scale. The toxicity grading scale was the same as that based upon the common toxicity criteria for a Phase II trial of high-dose sequential chemotherapy and peripheral blood stem cell autologous transplantation as initial therapy for patients with poor prognosis non-Hodgkin's lymphoma. (National Cancer institute document, draft 4/94: E2493.) Toxicity was graded on a scale from 0 to 4. No Grade 2 or greater toxic effects were observed, and in two patients that received 10 million mesenchymal stem cells, there appeared to be an increase in bone marrow cellularity.

EXAMPLE 3 Administration of Bone Marrow Cells and Mesenchymal Stem Cells to Breast Cancer Patients Treated with Chemotherapy

A breast cancer patient undergoes a diagnostic posterior iliac crest bone marrow aspiration and biopsy using a local anesthetic. A small portion (2 to 3 ml) of the aliquot (10 to 20 ml) of marrow is submitted for routine histologic testing and determination of tumor content using immunoperoxidase testing of cells grown in semisolid agar as described in Ross, et al., Blood., Vol. 82, pgs. 2605-2610 (1993). The remainder of the cells are cultured as hereinabove described. After at least 3 weeks in culture, samples of the mesenchymal stem cells are submitted for cell counting, cell viability (Trypan Blue), and cell surface immunophenotyping (testing with monoclonal antibodies SH2, SH3, and SH4). SH2 is produced by a hybridoma cell line assigned ATCC Accession No. HB10743. SH3 is produced by a hybridoma cell line assigned ATCC Accession No. HB10744. SH4 is produced by a hybridoma cell line assigned ATCC Accession No. HB10745. Samples also are submitted for detection of occult breast cancer.

The patient also undergoes placement of a pheresis central venous catheter, and receives subcutaneous injections of G-CSF (filgrastin) 10 μg/kg/day as described in Peters, et al., Blood, Vol. 81, pgs. 1709-1719 (1993); Chao, et al., Blood, Vol. 81, pgs. 2031-2035 (1993); Sheridan, et al., The Lancet, Vol. 2, pgs. 891-895 (1989); and Winter, et al., Blood, Vol. 82, pg. 293a (1993). G-CSF injections begin at least 3 days before the first pheresis is initiated. G-CSF therapy is withheld if the white blood cell count rises above 40,000/μL and is resumed once the white blood cell count drops to less than 20,000/μL.

If the patient is receiving only G-CSF as the vehicle for "mobilization" of peripheral blood progenitor cells, the patient must not have received chemotherapy within 4 weeks of the planned pheresis. If the patient has received both conventional chemotherapy and G-CSF treatment for mobilization, the patient must not have received chemotherapy within 10 days of the planned pheresis, and the white blood cell count must be at least 800/μL and the platelet count at least 30,000/μL.

Daily pheresis procedures are performed using a Cobe Spectra instrument (Cobe, Lakewood, Col.), and each cellular collection is cryopreserved using a controlled-rate liquid nitrogen freezer, until at least 15×108 mononuclear cells/kg are collected--(Lazarus, et al., Bone Marrow Transplant, Vol. 7, pgs. 241-246 (1991)). Each peripheral blood progenitor cell will be processed and cryopreserved according to previously published techniques. (Lazarus, et al., J. Clin, Oncol., Vol. 10, pgs, 1682-1689) (1992); Lazarus et al., (1991)).

Eight days before the patient is infused with the autologous peripheral blood progenitor cells, the patient receives chemotherapy over a period of 96 hours (4 days), with the following chemotherapy agents:

1. Cyclophosphamide in a total dosage of 6 g/m2 (1.5 g/m 2/day for 4 days) is given via continuous intravenous infusion at 500 mg/m2 in 1,000 ml normal saline every 8 hours.

2. Thiotepa in a total dosage of 500 mg/m2 /day for 4 days) is given via continuous intravenous infusion at 125 mg/2 in 1,000 ml normal saline every 24 hours.

3. Carboplatin in a total dosage of 1,800 mg/m2 (200 mg/m2 /day for 4 days) is given via continuous intravenous infusion at 200 mg/m2 in 1,000 ml of 5% dextrose in water every 24 hours.

The patient also receives 500 mg of mesna in 50 ml normal saline IV over 15 minutes every 4 hours for 6 days (144 hours), beginning with the first dose of cyclophosphamide.

At least 72 hours after the completion of the chemotherapy, the mesenchymal stem cells are harvested from tissue culture flasks. Cells are collected using bovine trypsin (which is deactivated with soybean trypsin inhibitor), suspended at 10×106 cells/ml in TC199 containing 1% human serum albumin (infusion medium), washed twice in infusion medium, resuspended at approximately 106 cells/ml, and injected slowly intravenously over 15 minutes to provide a total dosage of from 10 to about 5×106 cells.

The day after the patient receives the mesenchymal stem cells, the frozen autologous peripheral blood progenitor cells are removed from the liquid nitrogen refrigerator, transported to the patient in liquid nitrogen, submersed in a 37° C. to 40° C. sterile water bath, and infused rapidly intravenously without additional filtering or washing steps. GM-CSF in an amount of 250 μg/m2 then is given as a daily subcutaneous injection, beginning 3 hours after completion of the autologous blood progenitor cell infusion. The GM-CSF is given daily until the peripheral blood neutrophil count exceeds 1,000/μL for three consecutive days.

It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5226914 *16 Nov 199013 Jul 1993Caplan Arnold IMethod for treating connective tissue disorders
US5461034 *18 Jun 199324 Oct 1995Yissum Research Development Company Of The Hebrew University Of JerusalemOsteogenic growth polypeptides identified from regenerating bone marrow
Non-Patent Citations
Reference
1 *Hard. Demonstration of the tumorigenicity of transformed rat kidney cell lines by intravenous allotransplantation in the neonate. Int. Cancer: 30, 197 202 (1982).
2Hard. Demonstration of the tumorigenicity of transformed rat kidney cell-lines by intravenous allotransplantation in the neonate. Int. Cancer: 30, 197-202 (1982).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5942225 *23 Jul 199724 Aug 1999Case Western Reserve UniversityLineage-directed induction of human mesenchymal stem cell differentiation
US6010696 *25 Mar 19984 Jan 2000Osiris Therapeutics, Inc.Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US632896012 Mar 199911 Dec 2001Osiris Therapeutics, Inc.Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US664572725 May 200111 Nov 2003Stemcell Technologies Inc.Antibody compositions for preparing enriched mesenchymal progenitor preparations
US672313128 Feb 200120 Apr 2004The Cleveland Clinic FoundationComposite bone marrow graft material with method and kit
US693022222 Aug 200116 Aug 2005The Scripps Research InstituteIn vivo animal model of human leukemia
US693628121 May 200130 Aug 2005University Of South FloridaHuman mesenchymal progenitor cell
US70490723 Oct 200223 May 2006University Of South FloridaGene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state
US7098027 *23 Dec 200229 Aug 2006Renomedix Institute, Inc.Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
US71827811 Nov 200027 Feb 2007Regeneration Technologies, Inc.Cervical tapered dowel
US725587912 Aug 200314 Aug 2007Anthrogenesis CorporationPost-partum mammalian placenta, its use and placental stem cells therefrom
US730376910 Feb 20054 Dec 2007University Of South FloridaMethod for purifying pluri-differentiated mesenchymal progenitor cells
US731190413 Feb 200225 Dec 2007Anthrogenesis CorporationTissue matrices comprising placental stem cells, and methods of making the same
US731190513 Feb 200325 Dec 2007Anthrogenesis CorporationEmbryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US74423909 Jul 200428 Oct 2008University Of South FloridaMethod for enhancing engraftment of cells using mesenchymal progenitor cells
US746827622 Jun 200423 Dec 2008Anthrogenesis CorporationPlacental stem cells
US747053824 Jun 200430 Dec 2008Case Western Reserve UniversityCell-based therapies for ischemia
US74913884 Nov 199917 Feb 2009Osiris Therapeutics, Inc.Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
US768280323 Mar 2010Anthrogenesis CorporationImmunomodulation using placental stem cells
US76914156 Apr 2010University Of South FloridaMethod for preventing, or reducing the severity of, graft-versus-host disease using pluri-differentiated mesenchymal progenitor cells
US770009028 Dec 200620 Apr 2010Anthrogenesis CorporationCo-culture of placental stem cells and stem cells from a second source
US786304518 Jul 20084 Jan 2011Tigenix N.V.Isolation of skeletal precursor cells
US791477929 Oct 200729 Mar 2011Anthrogenesis CorporationTissue matrices comprising placental stem cells, and methods of making the same
US797683622 Dec 200812 Jul 2011Anthrogenesis CorporationTreatment of stroke using placental stem cells
US79939189 Aug 2011Anthrogenesis CorporationTumor suppression using placental stem cells
US805778815 Nov 2011Anthrogenesis CorporationPlacental stem cell populations
US805778915 Nov 2011Anthrogenesis CorporationPlacental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US805782619 May 200815 Nov 2011University Of South FloridaMethods for reducing graft-versus-host disease using pluri-differentiated mesenchymal progenitor cells
US81780848 Sep 200315 May 2012Quy Biosciences LimitedPharmaceutical kits comprising mesenchymal stem cells
US820270330 Jul 201019 Jun 2012Anthrogenesis CorporationPlacental stem cell populations
US821656610 Jul 2012Anthrogenesis CorporationTreatment of multiple sclerosis using placental stem cells
US826306511 Sep 2012Anthrogenesis CorporationTumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US829322323 Oct 2012Anthrogenesis CorporationTreatment of organ injuries and burns using placental stem cells
US8334135 *18 Dec 2012Yves Saint Laurent ParfumsStem cells from adipose tissue, and differentiated cells from said cells
US835437015 Jan 2013Garnet Biotherapeutics, Inc.Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders
US83674095 Feb 2013Anthrogenesis CorporationAmnion derived adherent cells
US84357887 May 2013Anthrogenesis CorporationTissue matrices comprising placental stem cells
US845525028 Dec 20064 Jun 2013Anthrogenesis CorporationCo-culture of placental stem cells and stem cells from a second source
US846065011 Jun 2013Anthrogenesis CorporationTreatment of inflammatory diseases using placental stem cells
US848669610 Feb 200516 Jul 2013Garnet Biotherapeutics, Inc.Cell populations which co-express CD49c and CD90
US854583316 May 20111 Oct 2013Anthrogenesis CorporationTreatment of radiation injury using placental stem cells
US856297223 Oct 200722 Oct 2013Anthrogenesis CorporationMethods and compositions for treatment of bone defects with placental cell populations
US85629736 Apr 201122 Oct 2013Anthrogenesis CorporationTreatment of sarcoidosis using placental stem cells
US858056327 Oct 200812 Nov 2013Anthrogenesis CorporationPlacental stem cells
US85863601 Jul 201019 Nov 2013Anthrogenesis CorporationMethod of producing erythrocytes without feeder cells
US859188316 May 201226 Nov 2013Anthrogenesis CorporationPlacental stem cell populations
US860346231 Mar 200410 Dec 2013University Of Utah Research FoundationStem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
US86141912 Feb 201224 Dec 2013Medipost Co., Ltd.Use of ICAM-1 for prevention or treatment of neurological diseases
US86175353 Nov 200631 Dec 2013Anthrogenesis CorporationCytotherapeutics, cytotherapeutic units and methods for treatments using them
US869121724 May 20128 Apr 2014Anthrogenesis CorporationPlacental stem cell populations
US872880524 Aug 200920 May 2014Anthrogenesis CorporationMethods and compositions for treatment of bone defects with placental cell populations
US875388313 May 201117 Jun 2014Anthrogenesis CorporationTreatment of psoriasis using placental stem cells
US882837620 Aug 20099 Sep 2014Anthrogenesis CorporationTreatment of stroke using isolated placental cells
US889525617 May 201225 Nov 2014Anthrogenesis CorporationImmunomodulation using placental stem cells
US891614610 May 201323 Dec 2014Anthrogenesis CorporationTreatment of inflammatory diseases using placental stem cells
US892696413 Jul 20116 Jan 2015Anthrogenesis CorporationMethods of generating natural killer cells
US896931529 Dec 20113 Mar 2015Anthrogenesis CorporationEnhancement of placental stem cell potency using modulatory RNA molecules
US904003531 May 201226 May 2015Anthrogenesis CorporationTreatment of pain using placental stem cells
US90457353 Apr 20082 Jun 2015The Cleveland Clinic FoundationEnrichment of tissue-derived adult stem cells based on retained extracellular matrix material
US907889814 Feb 201414 Jul 2015Anthrogenesis CorporationPlacental stem cell populations
US911534425 May 201225 Aug 2015Nc Medical Research Inc.Mesenchymal stem cell and a method of use thereof
US912100725 Jan 20111 Sep 2015Anthrogenesis CorporatinTreatment of bone-related cancers using placental stem cells
US913981315 Apr 201322 Sep 2015Anthrogenesis CorporationRenovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US914956916 May 20116 Oct 2015Anthrogenesis CorporationTreatment of diseases or disorders using placental stem cells
US919893826 Dec 20121 Dec 2015Antrhogenesis CorporationAmnion derived adherent cells
US92002536 Aug 20081 Dec 2015Anthrogenesis CorporationMethod of producing erythrocytes
US921620013 Aug 201222 Dec 2015Anthrogenesis CorporationTumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US92543026 Apr 20119 Feb 2016Anthrogenesis CorporationAngiogenesis using placental stem cells
US925524811 Oct 20139 Feb 2016Anthrogenesis CorporationMethod of producing erythrocytes without feeder cells
US933952016 Sep 201317 May 2016Anthrogenesis CorporationMethods and compositions for treatment of bone defects with placental cell populations
US943993119 Aug 201313 Sep 2016Medipost Co., LtdAdministering umbilical cord blood-derived mesenchymal stem cells to treat nerve injury
US20020058025 *20 Apr 200116 May 2002Prockop Darwin J.Stromal cell use
US20020160510 *13 Feb 200231 Oct 2002Hariri Robert J.Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US20030003084 *21 May 20012 Jan 2003Beerelli SeshiHuman mesenchymal progenitor cell
US20030032179 *13 Feb 200213 Feb 2003Hariri Robert J.Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030059414 *21 Sep 200127 Mar 2003Ho Tony W.Cell populations which co-express CD49c and CD90
US20030114367 *30 Sep 199919 Jun 2003Yehuda ShoenfeldComposition for the prevention and/or treatment of artherosclerosis
US20030180269 *13 Feb 200325 Sep 2003Hariri Robert J.Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030203483 *3 Oct 200230 Oct 2003Beerelli SeshiHuman mesenchymal progenitor cell
US20040058397 *9 Sep 200325 Mar 2004Thomas Terry E.Novel antibody compositions for preparing enriched mesenchymal progenitor preparations
US20040101959 *21 Nov 200227 May 2004Olga MarkoTreatment of tissue with undifferentiated mesenchymal cells
US20040121461 *23 Dec 200224 Jun 2004Renomedix Institute Inc.Cell fractions containing cells capable of differentiating into neural cells
US20040171147 *25 Nov 20032 Sep 2004Hariri Robert J.Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US20040208861 *12 May 200421 Oct 2004Philadelphia Health And Education CorporationStromal cell use
US20040229351 *31 Jul 200318 Nov 2004Anne-Marie RodriguezStem cells from adipose tissue, and differentiated cells from said cells
US20050059147 *9 Jul 200417 Mar 2005Beerelli SeshiHuman mesenchymal progenitor cell
US20050069527 *24 Jun 200431 Mar 2005Case Western Reserve UniversityCell-based therapies for ischemia
US20050142119 *10 Feb 200530 Jun 2005Beerelli SeshiHuman mesenchymal progenitor cell
US20050143420 *2 Dec 200430 Jun 2005Moutouh-De Parseval LaureMethods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050197283 *15 Apr 20058 Sep 2005Vascular Biogenics Ltd.Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20050233452 *10 Feb 200520 Oct 2005Neuronyx, Inc.Cell populations which co-express CD49c and CD90
US20050282276 *26 Jul 200522 Dec 2005Renomedix Institute, Inc.Cell fractions containing cells capable of differentiating into neural cells
US20060130852 *8 Sep 200322 Jun 2006Smith Roger Kenneth WPharmaceutical kits comprising mesenchymal stem cells
US20060154235 *23 Aug 200513 Jul 2006Takahiro OchiyaHuman hepatocyte-like cells and uses thereof
US20070053888 *6 Nov 20068 Mar 2007Hariri Robert JUse of umbilical cord blood to treat individuals having a disease, disorder or condition
US20070178071 *31 Mar 20042 Aug 2007Christof WestenfelderStem-cell, precursor cell, or target cell-based treatment of multiorgan failure and renal dysfunction
US20070224177 *7 Feb 200727 Sep 2007Ho Tony WCell populations which co-express CD49c and CD90
US20070231309 *19 Mar 20074 Oct 2007Neuronyx, Inc.Cell populations which co-express CD49c and CD90
US20070253931 *10 Jan 20071 Nov 2007Osiris Therapeutics, Inc.Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070264232 *2 May 200715 Nov 2007Neuronyx, Inc.Cell populations which co-express CD49c and CD90
US20070275362 *28 Dec 200629 Nov 2007James EdingerPlacental stem cell populations
US20080032401 *28 Dec 20067 Feb 2008James EdingerPlacental stem cell populations
US20080044848 *8 Jun 200721 Feb 2008Heidaran Mohammad APlacental niche and use thereof to culture stem cells
US20080060805 *31 Oct 200713 Mar 2008Cdx Gas, LlcMethod and system for accessing subterranean deposits from the surface and tools therefor
US20080089872 *4 Dec 200717 Apr 2008Beerelli SeshiMethod for purifying pluri-differentiated mesenchymal progenitor cells
US20080102058 *22 May 20071 May 2008Philadelphia Health And Education CorporationStromal cell use
US20080131966 *29 Oct 20075 Jun 2008Hariri Robert JRenovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US20080152624 *3 Aug 200726 Jun 2008Casper PaludanTumor suppression using placental stem cells
US20080152629 *31 Oct 200726 Jun 2008James EdingerPlacental stem cell populations
US20080206343 *12 Feb 200828 Aug 2008Edinger James WHepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations
US20080213228 *23 Oct 20074 Sep 2008Anthrogenesis CorporationMethods and Compositions for Treatment of Bone Defects with Placental Cell Populations
US20080241112 *10 May 20052 Oct 2008Christof WestenfelderTherapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
US20080241246 *15 Nov 20072 Oct 2008Arteriocyte Inc.Cell-based therapies for treating liver disease
US20080241870 *22 Jul 20052 Oct 2008National Centre For Cell ScinecesComposition For Creating an Artificial Bone Marrow Like Environment and Use Thereof
US20080248004 *13 Mar 20089 Oct 2008Renomedix Institute, Inc.Cell fractions containing cells capable of differentiating into neural cells
US20080254007 *19 May 200816 Oct 2008Beerelli SeshiHuman Mesenchymal Progenitor Cell
US20080286249 *5 Mar 200820 Nov 2008Varney Timothy RUse of mesenchymal stem cells for treating genetic diseases and disorders
US20080289395 *21 Aug 200727 Nov 2008Universal Scientific Industrial Co., Ltd.Testing machine
US20090053183 *16 Jun 200826 Feb 2009Neuronyx Inc.Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro
US20090068207 *11 Apr 200612 Mar 2009Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US20090104164 *26 Sep 200823 Apr 2009Celgene Cellular TherapeuticsAngiogenic cells from human placental perfusate
US20090123927 *18 Jul 200814 May 2009Tigenix N.V.Isolation of precursor cells and their use for tissue repair
US20090136471 *7 Nov 200828 May 2009Anthrogenesis CorporationTreatment of premature birth complications
US20090142831 *22 Dec 20084 Jun 2009Anthrogenesis CorporationPlacental stem cells
US20090214487 *11 Jan 200727 Aug 2009Timothy VarneyUse of mesenchymal stem cells for treating genetic diseases and disorders
US20090215434 *29 Apr 200927 Aug 2009Cvon Innovations LimitedMethod and system for distributing data to mobile devices
US20090252710 *29 Sep 20088 Oct 2009Celgene Cellular TherapeuticsTumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US20090291061 *21 May 200926 Nov 2009Riordan Neil HStem cell therapy for blood vessel degeneration
US20100040588 *18 Feb 2010Cryo-Cell International, Inc.Procurement, Isolation, and Cryopreservation of Endometrial/Menstrual Cells
US20100047213 *25 Feb 2010Andy ZeitlinCell composition and methods of making the same
US20100047214 *25 Feb 2010Abramson Sascha DMethods and Compositions for Treatment of Bone Defects with Placental Cell Populations
US20100047351 *20 Aug 200925 Feb 2010Andy ZeitlinTreatment of stroke using isolated placental cells
US20100098671 *7 Jun 200722 Apr 2010Modern Cell & Tissue Technologies Inc.composition for prevention or treatment of bone marrow damage
US20100098672 *19 Oct 200922 Apr 2010Timothy VarneyUse of mesenchymal stem cells for treating genetic diseases and disorders
US20100124569 *19 Nov 200920 May 2010Abbot StewartAmnion derived adherent cells
US20100143312 *23 Nov 200910 Jun 2010Hariri Robert JTreatment of diseases, disorders or conditions of the lung using placental cells
US20100167316 *3 Apr 20081 Jul 2010The Cleveland Clinic FoundationEnrichment of Tissue-Derived Adult Stem Cells Based on Retained Extracellular Matrix Material
US20100172830 *8 Jul 2010Cellx Inc.Extraembryonic Tissue cells and method of use thereof
US20100260847 *14 Oct 2010Anthrogenesis CorporationTissue matrices comprising placental stem cells
US20100291047 *18 Nov 2010Varney Timothy RUse of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders
US20100330052 *2 Sep 201030 Dec 2010Varney Timothy RUse of Mesenchymal Stem Cells for Treating Genetic Diseases and Disorders
US20110003387 *1 Jul 20106 Jan 2011Abbot StewartMethod of producing erythrocytes without feeder cells
US20110052670 *3 Mar 2011University Of Southern CaliforniaIdentification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
US20110158960 *30 Jun 2011Tigenix N.V.Isolation of precursor cells and their use for tissue repair
US20110158967 *30 Jun 2011NC MEDICAL RESEARCH INC. (75% interest)Mesenchymal stem cell and the method of use thereof
US20110171659 *19 Oct 201014 Jul 2011Abt Holding CompanyMultipotent Adult Stem Cells, Sources Thereof, Methods of Obtaining and Maintaining Same, Methods of Differentiation Thereof, Methods of Use Thereof and Cells Derived Thereof
US20110177045 *21 Jul 2011Varney Timothy RUse of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders
US20110177595 *21 Jul 2011Abt Holding CompanyMultipotent Adult Stem Cells, Sources Thereof, Methods of Obtaining and Maintaining Same, Methods of Differentiation Thereof, Methods of Use Thereof and Cells Derived Thereof
US20110206645 *25 Aug 2011Anthrogenesis CorporationTreatment of bone-related cancers using placental stem cells
US20110217271 *8 Sep 2011Anthrogenesis CorporationTreatment of diseases or disorders using placental stem cells
US20110217272 *8 Sep 2011Anthrogenesis CorporationTreatment of radiation injury using placental stem cells
US20110223141 *15 Sep 2011Anthrogenesis CorporationTreatment of brain or spinal cord injury using placental stem cells
US20110262393 *16 Nov 200927 Oct 2011Medipost Co., Ltd.Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
US20140030235 *26 Jul 201330 Jan 2014Osiris Therapeutics, Inc.Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders
US20150118206 *10 Jul 201230 Apr 2015Chandan GuhaStromal cell therapy in treatment of radiation injury
EP2204442A113 Oct 20087 Jul 2010Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Method of enriching stem cells in culture
EP2607477A15 May 200826 Jun 2013The Brigham and Women's Hospital, Inc.Multipotent stem cells and uses thereof
WO2001094541A2 *21 May 200113 Dec 2001University Of South FloridaHuman mesenchymal progenitor cell
WO2001094541A3 *21 May 200120 Jun 2002Univ South FloridaHuman mesenchymal progenitor cell
WO2002016559A2 *21 Aug 200128 Feb 2002The Scripps Research InstituteIn vivo animal model of human leukemia
WO2002016559A3 *21 Aug 20017 Aug 2003Scripps Research InstIn vivo animal model of human leukemia
WO2003029432A2 *3 Oct 200210 Apr 2003University Of South FloridaHuman mesenchymal progenitor cell
WO2003029432A3 *3 Oct 200215 Dec 2005Univ South FloridaHuman mesenchymal progenitor cell
WO2006092650A2 *22 Jul 20058 Sep 2006National Centre For Cell SciencesA composition for creating an artificial bone -marrow like environment and use thereof
WO2006092650A3 *22 Jul 200522 Feb 2007Nat Ct Cell SciencesA composition for creating an artificial bone -marrow like environment and use thereof
Classifications
U.S. Classification424/93.7, 435/372, 424/423, 424/422
International ClassificationA61F2/30, C07K16/28, C12N5/20, C12N5/00, A61L31/00, A61K35/12, A61K35/28, A61L27/38, A61F2/28, C12N5/077, C12N5/0775
Cooperative ClassificationC12N2501/39, A61F2/30756, A61L2430/10, C07K16/28, A61K35/28, A61F2/28, A61L31/005, A61L27/3834, A61L27/3843, C12N2533/18, A61K2035/124, C12N5/0663, A61L27/3895, C12N2501/2301
European ClassificationA61L27/38B14, A61L27/38H, A61L27/38D2, C12N5/06B13P1, C12N5/00S, A61K35/28, A61F2/28, C07K16/28, C12N5/06B21P, A61L31/00F
Legal Events
DateCodeEventDescription
24 Jan 1995ASAssignment
Owner name: CASE WESTERN RESERVE UNIVERSITY, OHIO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAYNESWORTH, STEPHEN E.;CAPLAN, ARNOLD I.;GERSON, STANTON L.;AND OTHERS;REEL/FRAME:007326/0476
Effective date: 19950113
9 Jun 1998CCCertificate of correction
15 Jul 1999ASAssignment
Owner name: OSIRIS THERAPEUTICS, INC., MARYLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CASE WESTERN RESERVE UNIVERSITY;REEL/FRAME:010086/0736
Effective date: 19990706
28 Sep 2001FPAYFee payment
Year of fee payment: 4
30 Sep 2005FPAYFee payment
Year of fee payment: 8
25 Sep 2009FPAYFee payment
Year of fee payment: 12
1 Nov 2013ASAssignment
Owner name: MESOBLAST INTERNATIONAL S?RL, SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OSIRIS THERAPEUTICS, INC.;REEL/FRAME:031533/0828
Effective date: 20131010
Owner name: MESOBLAST INTERNATIONAL SARL, SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OSIRIS THERAPEUTICS, INC.;REEL/FRAME:031533/0828
Effective date: 20131010